Single-cell Analysis Market Worth $5.6 billion by 2025 | Growing Focus on Personalized Medicine

PUNE, India, 2020-Aug-24 — /EPR Network/ —

The study involved four major activities in estimating the current size of the single-cell analysis market. Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets. The next step is to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size.

According MarketsandMarkets Research – The Single-cell Analysis Market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period.

Major Market Growth Drivers:

• Technological Advancements in Single-cell Analysis Products
• Increasing Government Funding for Cell-Based Research
• Growing Biotechnology and Bio-pharmaceutical Industries
• Wide Applications of Single-cell Analysis in Cancer Research
• Growing Focus on Personalized Medicine
• Increasing Incidence and Prevalence of Chronic and Infectious Diseases

Browse 225 market data Tables and 50 Figures spread through 252 Pages and in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254

The human cells segment dominates the single-cell analysis market.

Based on cell type, the market is segmented into human, animal, and microbial cells. The human cells segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the high utilization of human cells in research laboratories and academic institutes.

NGS is the fastest-growing segment of the single-cell analysis market.

Based on technique, the market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques. The NGS segment is projected to register the highest growth rate of 20.0% during the forecast period. The high growth of the NGS segment is driven by the increasing application of single-cell analysis products in drug discovery for cancer and other chronic diseases.

Recent Developments;

• In November 2019, QIAGEN launched QIAseq Multimodal Panels, which have been developed for consolidated targeted DNA and RNA enrichment and analyses. These panels save time and conserve samples that are of limited availability.
• In July 2019, QIAGEN partnered with Illumina with the aim to broaden the availability and use of NGS-based in vitro diagnostic (IVD) kits.
• In June 2019, Beckman Coulter acquired Cytobank, Inc. (US) to integrate Cytobank’s software into Beckman Coulter’s product portfolio to provide innovative solutions to customers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

The global single-cell analysis market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the market. The growth in this market can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

Prominent players in the single-cell analysis market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).